LyGenesis
OverviewSuggest Edit
LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. The Company's lead preclinical program is focused on liver regeneration for patients with end stage liver disease.
| Type | Private | |
| Founded | 2017 | |
| HQ | Pittsburgh, PA, US | Map |
| Website | lygenesis.com |
Recent NewsAll News
- LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology
- LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing
- LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology
- LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology
Latest Updates
| Employees (est.) (Apr 2022) | 6 | |
| Cybersecurity rating | A | More |
Key People/Management at LyGenesis
Michael Hufford
CEO
Paulo Fontes
Chief Medical Officer
Eric Lagasse
Chief Scientific Officer
LyGenesis Office Locations
LyGenesis has an office in Pittsburgh
Pittsburgh, PA, US (HQ)
1710 Murray Ave #200
Pittsburgh, PA, US
Shady Ave
LyGenesis Financials and Metrics
Summary Metrics
Founding Date | 2017 |
LyGenesis total Funding | $7 m |
LyGenesis latest funding size | $4 m |
Time since last funding | 3 years ago |
LyGenesis investors | Juvenescence, Longevity Vison Fund |
LyGenesis's latest funding round in October 2019 was reported to be $4 m. In total, LyGenesis has raised $7 m
LyGenesis Cybersecurity Score
LyGenesis Online and Social Media Presence
LyGenesis's Trends
LyGenesis News and Updates
January 20, 2022
LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology
PITTSBURGH, Jan. 20, 2022 /PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end stage renal disease, single enzyme deficiencies, and aging, announced today the publication of a new...
December 30, 2020
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing
PITTSBURGH, Dec. 30, 2020 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Under the IND, LyGenesis...
August 27, 2020
LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology
PITTSBURGH, Aug. 27, 2020 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was...
October 21, 2019
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology
PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology...
LyGenesis Blogs
November 19, 2021
Chief Medical Officer at LyGenesis, Professor Paulo Fontes, on the future of organ transplants
Permalink
November 19, 2021
LyGenesis adds orphan paediatric indications with large unmet needs to its drug development pipeline with novel approach which first aims to treat pediatric patients with Maple syrup urine disease
LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end stage renal disease and aging, announced today that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inb…
July 23, 2021
The Incrementalist Interview:
Listen in to hear Michael share the exciting progress to data that has
taken the human bio-reactor of lymph nodes, something that is hijacked for
use by cancer cells and instead use it for good to generate liver, and in
the future, pancreas, thymus and kidney. Delivering multiple organ
transplan…
January 04, 2021
LyGenesis’ FDA phase 2a clearance and $11m funding boost
Double bubble for biotech LyGenesis as it announces trial of its cell
therapy for patients with end-stage liver disease, and closure of $11m
convertible debt financing
September 02, 2020
Significant organ regeneration study progress for LyGenesis
Good news for organ regeneration as LyGenesis announces four peer-reviewed publications on its tech.Four peer-reviewed papers cover LyGenesis’ work on liver and kidney regeneration on an ectopic basis. Being able to move away from long transplants lists towards purpose-grown, histocompatible organs …
LyGenesis Frequently Asked Questions
When was LyGenesis founded?
LyGenesis was founded in 2017.
Who are LyGenesis key executives?
LyGenesis's key executives are Michael Hufford, Paulo Fontes and Eric Lagasse.
How many employees does LyGenesis have?
LyGenesis has 6 employees.
Who are LyGenesis competitors?
Competitors of LyGenesis include ENTEROME Bioscience, Precise Bio and Winnoz Technology.
Where is LyGenesis headquarters?
LyGenesis headquarters is located at 1710 Murray Ave #200, Pittsburgh.
Where are LyGenesis offices?
LyGenesis has an office in Pittsburgh.
How many offices does LyGenesis have?
LyGenesis has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies